Stay updated on Azacitidine and Pembrolizumab in MDS Clinical Trial
Sign up to get notified when there's something new on the Azacitidine and Pembrolizumab in MDS Clinical Trial page.

Latest updates to the Azacitidine and Pembrolizumab in MDS Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange DetectedThe page's location information section was updated: 'Texas Locations' was replaced with a general 'Locations' section and a 'Texas' entry added; the 'HHS Vulnerability Disclosure' link was removed, and the page revision advanced from v3.3.2 to v3.3.3.SummaryDifference0.2%

- Check18 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2 appears to be a minor version change and does not alter study details or visible content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check39 days agoChange DetectedRevision updated from v3.2.0 to v3.3.1.SummaryDifference0.1%

- Check47 days agoChange DetectedThe funding/operating status notice has been removed from the page; the informational block about potential updates and NIH operations is no longer displayed.SummaryDifference0.4%

- Check61 days agoChange DetectedPage content remains unchanged; only minor formatting and layout tweaks were observed without altering study details such as eligibility criteria, outcomes, or contacts. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check90 days agoChange Detected- Added a government operations notice and operating details, plus a new v3.2.0 revision. - Removed the previous v3.1.0 revision.SummaryDifference3%

Stay in the know with updates to Azacitidine and Pembrolizumab in MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Azacitidine and Pembrolizumab in MDS Clinical Trial page.